1-4 of 4
Randy Davis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vania T.M Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian Li, Marcelo Capra, Angelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Low, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalinska, Meletios Athanasios Dimopoulos
Journal: Blood
Blood (2023) 142 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2023-178009
Published: 2023
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Robert M. Rifkin, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Kihyun Kim, MD PhD, Francesco Di Raimondo, MD, Meletios A Dimopoulos, Katja Weisel, MD, Bertrand Arnulf, MD, Roman Hajek, MD, Vania T. M. Hungria, MD PhD, Andrew Spencer, Randy Davis, PhD, Antonio Riccio, PhD MBA, Chanbin Kim, Jodie Wilkes, Ruth Rutledge, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-139181
Published: 2020
Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Anders Österborg, Birgitte Biilmann Ronn, Roxanne C Jewell, Thomas J Kipps, Jiri Mayer, Stephan Stilgenbauer, Cathy D Williams, Andrzej Hellmann, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny, Martin JS Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Michael Arning, Nedjad Losic, Randy Davis, Joris Wilms, Charlotte A Russell, William G Wierda
Journal: Blood
Blood (2009) 114 (22): 3433.
https://doi.org/10.1182/blood.V114.22.3433.3433
Published: 2009